Biblioteca Humberto Rosselli Quijano
[artículo]
| Título : |
Memantine augmentation in treatment resistant obsessive compulsive disorder : An open label trial |
| Tipo de documento: |
texto impreso |
| Autores: |
Elias Aboujaoude, Autor ; John J. Barry, Autor ; Nona Gamel, Autor |
| Fecha de publicación: |
2022 |
| Artículo en la página: |
pp. 51-55 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Etiquetas: |
Farmacoterapia, Combinación, Antagonistas de aminoácidos excitatorios, Memantina - administración y posología, Trastorno obsesivo-compulsivo - diagnóstico |
| Resumen: |
Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). We report on the first open-label study to test the hypothesis that memantine, a noncompetitive glutamate antagonist, will result in a clinically meaningful reduction in OCD symptoms in adults with treatment-resistant OCD. |
| Link: |
./index.php?lvl=notice_display&id=29529 |
in Journal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 1 (Febrero) . - pp. 51-55
[artículo] Memantine augmentation in treatment resistant obsessive compulsive disorder : An open label trial [texto impreso] / Elias Aboujaoude, Autor ; John J. Barry, Autor ; Nona Gamel, Autor . - 2022 . - pp. 51-55. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 1 (Febrero) . - pp. 51-55
| Etiquetas: |
Farmacoterapia, Combinación, Antagonistas de aminoácidos excitatorios, Memantina - administración y posología, Trastorno obsesivo-compulsivo - diagnóstico |
| Resumen: |
Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). We report on the first open-label study to test the hypothesis that memantine, a noncompetitive glutamate antagonist, will result in a clinically meaningful reduction in OCD symptoms in adults with treatment-resistant OCD. |
| Link: |
./index.php?lvl=notice_display&id=29529 |
|
